Thyroid dysfunction in perimenopausal and postmenopausal women

Menopause International

Volumn 13, Issue 1, 2007, Pages 8-13

  Pearce, Elizabeth n ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HYPOTHYROIDISM; MENOPAUSE; THYROID STIMULATING HORMONE; THYROTOXICOSIS; THYROXINE

Indexed keywords

ALUMINUM HYDROXIDE; AMIODARONE; ANTACID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; CARBIMAZOLE; COLESTYRAMINE; DROLOXIFENE; ESTROGEN; FERROUS SULFATE; HORMONE BINDING PROTEIN; LEVOTHYROXINE; LIOTHYRONINE; LUGOL; PROPYLTHIOURACIL; PROTON PUMP INHIBITOR; RADIOACTIVE IODINE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SUCRALFATE; TAMOXIFEN; THIAMAZOLE; THIONAMIDE DERIVATIVE; THYROID HORMONE; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROXINE; THYROXINE BINDING GLOBULIN; UNINDEXED DRUG;

ADJUVANT THERAPY; AGRANULOCYTOSIS; ARTHRALGIA; BLEEDING DISORDER; CARDIOVASCULAR RISK; CLIMACTERIUM; CLINICAL FEATURE; COGNITIVE DEFECT; COMA; CONGESTIVE HEART FAILURE; DEPRESSION; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; ESTROGEN THERAPY; EUTHYROIDISM; EYE DISEASE; FEMALE; FEVER; FRAGILITY FRACTURE; GOITER; GRAVES DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTHYROIDISM; HYPOCALCEMIA; HYPOTHYROIDISM; INTESTINE PSEUDOOBSTRUCTION; JAUNDICE; LIOTHYRONINE BLOOD LEVEL; LOW DRUG DOSE; MATERNAL AGE; MOOD DISORDER; NERVE INJURY; PATIENT MONITORING; PERICARDIAL EFFUSION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PSYCHOSIS; RASH; RECURRENT LARYNGEAL NERVE PALSY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SORE THROAT; SYMPTOMATOLOGY; TACHYCARDIA; THYROID DISEASE; THYROID FUNCTION TEST; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; URTICARIA;

FEMALE; HUMANS; HYPOTHYROIDISM; MENOPAUSE; THYROID FUNCTION TESTS; THYROTOXICOSIS; THYROTROPIN; THYROXINE;

EID: 34247890027     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1258/175404507780456746     Document Type: Review

References (59)

1. Hollowell J, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489–99.
2. Pearce EN, Farwell A, Braverman LE. Thyroiditis. N Engl J Med 2003;348:2646–55.
3. Tunbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol 1977;7:481–93.
4. Sawin CT, Castelli WP, Hershman JM, et al. The aging thyroid: thyroid deficiency in the Framingham Study. Arch Intern Med 1985;145:1386–8.
5. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado Thyroid Disease Prevalence Study. Arch Intern Med 2000;160:526–34.
6. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249–52.
7. Pearce EN, Braverman LE. Thyroid disease in perimenopausal and postmenopausal women. Infertility and Reproductive Medicine Clinics of North America 2001;12:585–603.
8. Schindler AE. Thyroid function and menopause. Gynecol Endocrinol 2003;17:79–85.
9. Eaton SEM, Webster J, Allahabadia A. Thyroid disease and the menopausal woman. J Br Menopause Soc 2003;9:82–4.
10. Bottiglioni F, de Aloysio D, Nicoletti G, et al. A study of thyroid function in the pre- and post-menopause. Maturitas 1983;5:105–14.
11. Massoudi MS, Meilahn EN, Orchard TJ, et al. Prevalence of thyroid antibodies among healthy middle-aged women: findings from the Thyroid Study in Health Women. Ann Epidemiol 1995; 5:229–33.
12. Sowers M, Luborsky J, Perdue C, Araujo KL, Goldman MB, Harlow SD. Thyroid stimulating hormone (TSH) concentrations and menopausal status in women at the mid-life. Clin Endocrinol 2003;58:340–7.
13. Lopez-Achigar E, Collazo C, Blanco R, Raymondo S. Supporting the cost-effectiveness of a thyroid testing algorithm. Clin Chim Acta 2000;296:213–15.
14. American College of Physicians. Clinical guideline, part 1: screening for thyroid disease. Ann Intern Med 1998;129:141–3.
15. Ladenson PW, Singer PA, Ain KB, et al. American ThyroidAmerican Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000;160:1573–5.
16. Danese MD, Powe NR, Sawin CT, et al. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA 1996;276:285–92.
17. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 2005;90:581–5.
18. Surks MI, Ortiz E, Daniels GH, Sawin CT, et al. Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA 2004;291:228–38.
19. US Preventive Services Task Force. Screening for thyroid disease: recommendation statement. Ann Intern Med 2004;140:125–7.
20. Association for Clinical Biochemistry, British Thyroid Association, British Thyroid Foundation. UK Guidelines for the Use of Thyroid Function Tests. 2006. Available at www.acb.org. uk/docs/TFTguidelinefinal.pdf (accessed December 2006).
21. Doucet J, Trivalle C, Chassagne P, et al. Does age play a role in clinical presentation of hypothyroidism? J Am Geriatr Soc 1994;42:984–6.
22. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004;363: 793–803.
23. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol 1999;50:655–9.
24. Lincoln SR, Ke RW, Kutteh WH. Screening for hypothyroidism in infertile women. J Reprod Med 1999;44:455–7.
25. Cooper DS. Subclinical hypothyroidism. N Engl J Med 2001;345: 260–5.
26. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty year follow-up of the Whickham survey. Clin Endocrinol (Oxf) 1995;43:55–68.
27. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501–9.
28. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 2002;137:904–14.
29. O'Brien T, Dineen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993;68:860–6.
30. Pearce EN. Hypothyroidism and dyslipidemia: modern concepts and approaches. Curr Cardiol Rep 2004;6:451–6.
31. Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001;358:861–5.
32. Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005;165:2467–72.
33. Cappola AR, Fried LP, Arnold M, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006;295: 1033–41.
34. Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 1999;340:424–9.
35. Ain KB, Mori Y, Refetoff S. Reduced clearance rate of thyroxinebinding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab 1987;65:689–96.
36. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001;344:1743–9.
37. Mamby CC, Love RR, Lee KE. Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J Clin Onc 1995;13:854–7.
38. Anker GB, Lonning PE, Aakvaag A, et al. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scand J Clin Lab Invest 1998;58:103–7.
39. Marqusee E, Braverman LE, Lawrence JE, et al. The effects of droloxifene and estrogen on thyroid function in postmenopausal women. J Clin Endocrinol Metab 2000;85:4407–10.
40. Caresini G, Morganti S, Rebecchi I, et al. A one year follow-up on the effects of raloxifene on thyroid function in postmenopausal women. Menopause 2004;11:176–9.
41. Siraj ES, Gupta MK, Reddy SS. Raloxifene causing malabsorption of levothyroxine. Arch Intern Med 2003;163:1367–70.
42. Garwood CL, Van Schepen KA, McDonough RP, Sullivan AL. Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene. Pharmacotherapy 2006;26:881–5.
43. Danese MD, Ladenson PW, Meinert CL, Powe NR. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000;85:2993–3001.
44. Meier C, Staub JJ, Roth CB, Guglielmetti M, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double-blind placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001;86:4860–6.
45. Monzani F, Di Bello V, Caraccio N, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2001;86:1110–15.
46. Caraccio N, Natali A, Sironi A, et al. Muscle metabolism and exercise tolerance in subclinical hypothyroidism: a controlled trial of levothyroxine. J Clin Endocrinol Metab 2005;90:4057–62.
47. Monzani F, Del Guerra P, Caraccio N, et al. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-thyroxine treatment. Clin Investig 1993;71:367–71.
48. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-thyroxine therapy in subclinical hypothyroidism. A doubleblind, placebo-controlled trial. Ann Intern Med 1984;101:18–24.
49. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA, Lindstedt G. A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical’ hypothyroidism. Clin Endocrinol (Oxf) 1988;29:63–75.
50. Custro N, Scafidi V. Mild hyperthyroidism with inappropriate secretion of TSH in postmenopausal women. Acta Endocrinologica 1986;111:204–8.
51. Krassas GE, Pontikides N, Kaltsas T, et al. Menstrual disturbances in thyrotoxicosis. Clin Endocrinol 1994;40:641–4.
52. Trivalle C, Doucet J, Chassagne P, et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 1996;44:50–3.
53. Papi G, Pearce EN, Braverman LE, et al. A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only. Am J Med 2005;118:349–61.
54. Pearce EN. The diagnosis and management of thyrotoxicosis. BMJ 2006;332:1369–73.
55. Harvey RD, McHardy KC, Reid IW, et al. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridium cross-links as specific urinary markers. J Clin Endocrinol Metab 1991;72:1189–94.
56. Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994;4:319–26.
57. Majima T, Komatsu Y, Doi K, et al. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. J Bone Miner Metab 2006;24:105–13.
58. Abraham P, Avenell A, Watson WA, et al. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 2005;(4):CD003420.
59. Toft AD. Clinical practice: subclinical hyperthyroidism. N Engl J Med 2001;354:512–16.